Abstract
Brain-derived neurotrophic factor (BDNF) is a potential biomarker of response to treatment in psychiatric disorders. As it plays a role in the pathophysiological development of schizophrenia and bipolar disorder, it is of interest to study its role in predicting therapeutic responses in both conditions. We carried out a systematic review of the literature, looking for differences in baseline BDNF levels and the Val66Met BDNF polymorphism in these disorders between responders and non-responders, and found information showing that the Val/Val genotype and higher baseline BDNF levels may be present in patients that respond successfully to pharmacological and non-pharmacological treatments. However, there is still limited evidence to support the role of the Val66Met polymorphism and baseline BDNF levels as predictors of treatment response.
Original language | English |
---|---|
Article number | 11204 |
Journal | International Journal of Molecular Sciences |
Volume | 25 |
Issue number | 20 |
DOIs | |
State | Published - Oct 2024 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2024 by the authors.
Keywords
- BDNF
- biomarkers
- bipolar disorder
- neurotrophins
- schizophrenia
- treatment refractoriness
- treatment resistance
- treatment response